GENESIS Pharma
Edward Lysen is an experienced pharmaceutical executive currently serving as a Strategic Expansion Advisor at GENESIS Pharma, starting January 2024, after a successful tenure as Senior Director of Partner Markets at Alnylam Pharmaceuticals from October 2019 to December 2023. Lysen has held various senior positions, including Country Manager for Central and Eastern Europe & Middle East Africa at Alnylam, Senior Director at Biogen International GMBH, and General Manager at Biogen Idec and Wyeth. With a strong background in strategic market development and management, Lysen has also contributed to the Dutch pharmaceutical industry as Vice Chairman of NEFARMA and held pivotal roles at Organon Turkey and Nippon Organon K.K. Lysen holds a Master's degree in Corporate & Tax Law from Utrecht University.
This person is not in any teams
This person is not in any offices
GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative pharmaceutical products for severe and rare diseases in Central and Eastern Europe. Founded in 1997 in Greece, GENESIS Pharma S.A. was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. In 1999, business activities were expanded in Cyprus through the creation of GENESIS Pharma (Cyprus) Ltd, and later on, in markets of Southeast Europe. GENESIS Pharma (Cyprus) Ltd, an affiliate (sister) company, now operates in Central and Eastern Europe, through its subsidiaries in Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Slovenia (EU) as well as North Macedonia and Serbia (Non-EU). GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with leading international pharma companies committed to cutting-edge R&D as well as biopharma companies with disruptive innovations for the development of targeted, specialized treatments for orphan diseases. For more information, please visit www.genesispharmagroup.com and www.genesispharma.com